Liquidia (NASDAQ:LQDA) Insider Sells $3,703,000.00 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Rajeev Saggar sold 50,000 shares of the company’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $74.06, for a total value of $3,703,000.00. Following the completion of the sale, the insider owned 142,265 shares of the company’s stock, valued at approximately $10,536,145.90. The trade was a 26.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Rajeev Saggar also recently made the following trade(s):

• On Monday, August 17th, Rajeev Saggar sold 29,534 shares of Liquidia stock. The stock was sold at an average price of $76.84, for a total value of $2,269,392.56.
• On Monday, July 13th, Rajeev Saggar sold 9,926 shares of Liquidia stock. The shares were sold at an average price of $71.51, for a total value of $709,808.26.

Liquidia Trading Down 3.4%

Liquidia stock opened at $68.62 on Friday. The firm has a 50 day moving average of $79.29 and a 200 day moving average of $56.21. The firm has a market capitalization of $6.14 billion, a price-to-earnings ratio of 50.09 and a beta of 0.58. Liquidia Corporation has a 12-month low of $21.15 and a 12-month high of $93.61. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63.

Liquidia (NASDAQ:LQDA) last released its earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The firm had revenue of $171.68 million for the quarter, compared to the consensus estimate of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%.Liquidia’s revenue was up 1842.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.49) EPS. As a group, research analysts predict that Liquidia Corporation will post 2.57 earnings per share for the current year.

Institutional Trading of Liquidia

A number of institutional investors and hedge funds have recently bought and sold shares of LQDA. GSA Capital Partners LLP grew its position in shares of Liquidia by 63.6% during the fourth quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock valued at $2,179,000 after purchasing an additional 24,555 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Liquidia by 63.3% in the first quarter. The Manufacturers Life Insurance Company now owns 58,265 shares of the company’s stock worth $2,199,000 after purchasing an additional 22,592 shares during the last quarter. State of New Jersey Common Pension Fund D purchased a new stake in shares of Liquidia in the fourth quarter worth about $709,000. WCG Wealth Advisors LLC lifted its position in shares of Liquidia by 98.2% in the fourth quarter. WCG Wealth Advisors LLC now owns 54,411 shares of the company’s stock worth $1,877,000 after buying an additional 26,957 shares in the last quarter. Finally, Handelsbanken Fonder AB bought a new position in Liquidia during the second quarter valued at approximately $1,993,000. 64.54% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently weighed in on LQDA. Stephens set a $130.00 target price on shares of Liquidia in a report on Friday, July 24th. Jefferies Financial Group restated a “buy” rating and issued a $60.00 price objective on shares of Liquidia in a research report on Monday, May 11th. Wells Fargo & Company upped their price objective on Liquidia from $62.00 to $108.00 and gave the stock an “overweight” rating in a research note on Thursday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research report on Friday, July 17th. Finally, BTIG Research lifted their target price on Liquidia from $109.00 to $111.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Liquidia has an average rating of “Hold” and a consensus target price of $98.08.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).